Bank of New York Mellon’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-1,005,186
| Closed | -$12.5M | – | 4386 |
|
|
2016
Q4 | $12.5M | Sell |
1,005,186
-20,179
| -2% | -$243K | ﹤0.01% | 1841 |
|
|
2016
Q3 | $14M | Sell |
1,025,365
-10,516
| -1% | -$106K | ﹤0.01% | 1680 |
|
|
2016
Q2 | $7.66M | Buy |
1,035,881
+178,750
| +21% | +$1.34M | ﹤0.01% | 1987 |
|
|
2016
Q1 | $5.48M | Sell |
857,131
-11,589
| -1% | -$65K | ﹤0.01% | 2130 |
|
|
2015
Q4 | $5.43M | Sell |
868,720
-15,964
| -2% | -$105K | ﹤0.01% | 2167 |
|
|
2015
Q3 | $5.17M | Sell |
884,684
-138,221
| -14% | -$1.06M | ﹤0.01% | 2210 |
|
|
2015
Q2 | $8.46M | Buy |
1,022,905
+57,629
| +6% | +$510K | ﹤0.01% | 2050 |
|
|
2015
Q1 | $7.95M | Buy |
965,276
+29,924
| +3% | +$221K | ﹤0.01% | 2060 |
|
|
2014
Q4 | $6.43M | Sell |
935,352
-5,058
| -0.5% | -$31.6K | ﹤0.01% | 2171 |
|
|
2014
Q3 | $5.08M | Sell |
940,410
-46,633
| -5% | -$272K | ﹤0.01% | 2308 |
|
|
2014
Q2 | $6.29M | Buy |
987,043
+265,438
| +37% | +$1.83M | ﹤0.01% | 2194 |
|
|
2014
Q1 | $5.82M | Buy |
721,605
+7,889
| +1% | +$61.4K | ﹤0.01% | 2231 |
|
|
2013
Q4 | $4.87M | Sell |
713,716
-87,056
| -11% | -$470K | ﹤0.01% | 2309 |
|
|
2013
Q3 | $14.7M | Sell |
800,772
-35,277
| -4% | -$685K | ﹤0.01% | 1598 |
|
|
2013
Q2 | $14.6M | Buy |
+836,049
| New | +$14.8M | ﹤0.01% | 1574 |
|
Other funds holding ARIA
Bank of New York Mellon's ARIA Position: Q1 2017 in Review
Bank of New York Mellon sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 1,005,186 shares — an estimated $12.5M sold.
Bank of New York Mellon first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $14.7M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- Bank of New York Mellon reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- Bank of New York Mellon sold 1,005,186 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $12.5M.
- Bank of New York Mellon first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Bank of New York Mellon's Ariad Pharmaceuticals Inc position peaked at $14.7M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on Bank of New York Mellon's 13F filing for Q1 2017, filed 3 May 2017.